talquetamab + daratumumab

The combination of **talquetamab** (a GPRC5D-directed bispecific T-cell engager) and daratumumab (an anti-CD38 monoclonal antibody) is an investigational regimen evaluated primarily in relapsed/refractory multiple myeloma. Talquetamab works by redirecting T cells to malignant plasma cells via binding to GPRC5D and CD3, forming an immune synapse and inducing cytotoxicity. Daratumumab targets CD38, leading to direct cancer cell death, antibody-dependent cell-mediated cytotoxicity, and immune modulation. The rationale for combination is based on both drugs acting on different antigens on myeloma cells, enhancing antitumor activity and potentially depleting regulatory T-cells that may otherwise dampen the immune response[2][3][5][6].

Other names

talquetamab plus daratumumab